Enzolytics (ENZC) Stock Price & Analysis
ENZC Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- N/A
- Previous Close
- $0.01
- Volume
- N/A
- Average Volume (3M)
- 6.99M
- Market Cap
- $1.93M
- Enterprise Value
- $4.94T
- Total Cash (Recent Filing)
- $200.00M
- Total Debt (Recent Filing)
- $996.34K
- Price to Earnings (P/E)
- ―
- Beta
- 1.09
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
ENZC FAQ
What is Enzolytics’s market cap?
When is Enzolytics’s upcoming earnings report date?
Is Enzolytics overvalued?
Does Enzolytics pay dividends?
What is Enzolytics’s EPS estimate?
How many shares outstanding does Enzolytics have?
Which hedge fund is a major shareholder of Enzolytics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Enzolytics
Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven Sharabura
- Employees
- 1
- Website
- enzolytics.com
- Address
- 1101 Raintree Circle, Allen, TX, 75013, US
